595
ONKOLOGIE3418040010760120167227269329388409453
/8408040010731
Onkologie.9168040010761110147195214263313331375390
2025;19(4):214-2181326804001074487128172185223260284326347362406446485513552592631
/20028040010731
www.onkologiecs.cz48658040010765133201214262311348396415464514532576617652669709748
2141348020012657111164
PŘEHLEDOVÉ341200012660124182256312369444520587645
ČLÁNKY1008200012660115187259327395
Durvalumab34136001063778114152189220259313354389
v746360010636
léčbě7983600106296196132164
limitovaného97836001062947100118150189226263304335377417
stadia141136001063163100139157196
SCLC16233600106316697130
Durvalumab3409200298167307396527652716854105911841326
v17149200298127
léčbě1890920029866191299442568
limitovaného25069200298661303353994856217438681006113112711408
stadia39639200298104190317458522647
SCLC46599200298129270389526
Juraj3401320013745110151209239
Kultan6021320013767129160200259323
Klinika340148001336087111172197247301
plicních664148001336389114162223248296356
nemocí10441480013361116207268317342
a14091480013353
tuberkulózy,1486148001333696158214249301361387447492547564
Fakultní20731480013354102153214239275335360
nemocnice24561480013361116208268318378403452505
Olomouc29841480013376103163254315375424
Přes340199001215384132171
všeobecné537199001214886136191247297341396445
pokroky10081990012157112158191245291341
systémové1375199001213986125158206288343389437
léčby1838199001212473118173218
solidních2082199001214094117139195249271315369
zhoubných2477199001214397151205261316361403457
nádorů29601990012156103159213245299
v32851990012148
posledních33591990012157112150173222278332354398452
desetiletích3402130012158109149200233257280331365388433489
zůstávalo8562130012144100139173223270319342398
limitované1282213001212447131155188243291340396447
stadium1756213001214175125182205260345
malobuněčného21292130012185134157213271327383434480536587644700
karcinomu2857213001214897130175198254310395450
plic3335213001215882105151
jedním3513213001212576134190213298
z3402270012143
nemnohých,3992270012155104186241295349394436490510
u9252270012154
kterého995227001214782130162210265319
nedošlo13302270012155104160214252275329
k16742270012147
implementaci17372270012123105161184233315365419450498542563
novějších23162270012156110156203226264286329383
typů2715227001213381138192
protinádorové2923227001215789142174196250296352406438491537585
terapie3524227001213381112160215238287
(imunoterapie340241001212850132186240294326374406454509532581
nebo9422410012156105161216
cílené117924100121456791141195245
léčby1445241001212373117173218
pomocí16842410012157112195249294316
tyrozinkinázových2021241001213382114168208231285331355409456498552598647690744
inhibitorů)2786241001212478132154210233265318350404428
do32362410012156110
terapeutického3367241001213381113161216267321353375419340255001214796152206
algoritmu.573255001214972128183215238271354409429
S10292550012150
tím,1105255001213456140160
logicky,1292255001212479135158202248298314
souvisel1632255001214095151199222260311334
omezený19932550012155139189232282337383
progres2402255001215890145201233283322
v27512550012148
parametrech28262550012158106138186270320353385435480535
celkového3387255001214694118164218264313369424
přežití,340269001215688135177199230252271
resp.626269001213280118173191
5letého833269001215071120152199253306
přežití1155269001215687135177198230252
pacientů.14222690012156103146168216270301354373
V18102690012155
současné1880269001214093146190236274327376
době22712690012156109164214
jsme2500269001212461142191
svědky2706269001213987134189234283
zavedení3004269001214290135183238287340362
adjuvantní33812690012148103125178224271325355409430
imunoterapie3402830012123105159214268299348379427483505554
po9102830012157112
absolvování10382830012148104142197220267320366413468490
chemoradioterapie1544283001214498148230285317364420442496528576608655711733783
v23422830012149
reálné2407283001213281128150205254
klinické267728300121477193147169213258306
praxi2999283001215789136183205
pro3220283001215789143
limitované3379283001212345127150182235281328383432
stadium340297001214072120176198252334
malobuněčného6922970012183130153207263318372421466520569624678
karcinomu1388297001214795127170192246300383437
plic.1843297001215780102145166
Tato2027297001215090122175
možnost22202970012183137178233287325358
byla25962970012157102126173
dosažena27872970012156110148196239287342389
na31942970012156103
základě3315297001214291137161208263313
výsledků3646297001214897136340311001212372128174227
klinické58331100121467092146167211256303
studie902311001213972125180202251
ADRIATIC,11683110012161126179202261303326383404
v15883110012148
níž1651311001215577119
durvalumab17853110012156110141191238260313395441497
(PD-L12297311001212979143176224265
inhibitor)2578311001212377131153208230262314346371
podávaný29653110012156111166213258305359403
u33843110012155
pacientů34543110012157104147169218272303356
po3403250012156111
absolvování4663250012148103141195217264316362409462484
konkomitantní966325001214698152197250331353385432486517570592
chemoradioterapie1574325001214497146228282313360415437490521569601647702725773
na23633250012155101
bázi24803250012156104145167
platiny,2663325001215679125156178232276290
u29693250012155
kterých3039325001214781129160209251305
nedošlo33593250012155104160213251273326
po37013250012156111
iniciální34033900121237798141163209231284306
léčbě661339001212472116171220
k8973390012146
progresi,959339001215688140195226275312334353
prokázal1327339001215788141187234276324346
statisticky1688339001214072119150172209241263306351399
signifikantní2103339001213960115168190218242287335389419473495
zlepšení2613339001214265113169206255309330
v29593390012147
primárních3022339001215688110191238268323344387441
cílových347833900121446690143189238280333
parametrech3403530012157105137185268318350382431476531
–8973530012151
doby9743530012157111168214
do12143530012157111
progrese1352353001215789143199231280319369
a17473530012149
celkového1822353001214594117163216263311366421
přežití2269353001215789139181204236258
oproti25543530012155111144198230252
kontrolnímu28333530012147100155187218272296350372455509
studijnímu3369353001214073127183205228283305388442
rameni340367001213382166217273295
s6633670012140
placebem.730367001215882130175224281333417438
Tato1195367001215192125179
skutečnost1401367001214187143176225271326382421455
byla18833670012158104128176
reflektována2087367001213383112139189236272326374422478526
regulačními2640367001213484141196219267312367390474497
úřady3164367001215689137194242
Evropské3433367001215097131185243282329378
unie3403810012155109131181
v5393810012149
únoru,6063810012155110164196250270
resp.895381001213281120175194
březnu1108381001215788137179234288
2025,14143810012152101149199217
které1650381001214681130161210
doporučily18793810012156110167222253308352374396442
podání23403810012157112168215269292
durvalumabu26503810012157110142192240262316398445501555
v32243810012148
této3291381001213381114167
indikaci.3477381001212377133155201249293315334
Klíčová340397001246189117161218270322
slova:679397001244371128180232257
malobuněčný9533980012183130154208265320374424469524569
karcinom1539398001214795127171194248303386
plic1942398001215780103147
(SCLC),2107398001212874131177232261279
limitované2404398001212346128151184237284332386436
stadium,2858398001213973121177200254336357
imunoterapie,32323980012123106160215269302350383431487510560579
durvalumab.3404120012156111144195243267321405453509529
Durvalumab3404390012470129167223276304362449502562
in922439001242887
the1029439001243796149
treatment1199439001243675129182219306359419455
of1675439001245792
limited-stage1787439001242855142170207260320354397435488547600
SCLC24084390012454113164222
Despite3404570012165114152206228259306
general6614570012155103157205236282304
advances9804570012148102148194247290337375
in1370457001212376
the1461457001213285134
systemic1610457001213884122154201282304346
treatment1971457001213363111157188268317370400
of2387457001215381
solid2483457001213992114135190
malignant26884570012181127149171224277323376407
tumours3110457001213285165218271302340
in3465457001212376
recent3556457001213380124171224255
decades,3404710012156106151200256305344365
limited-stage731471001212447129152185233290321361394442498548
small13054710012140122170193215
cell1547471001214593117139
lung1713471001212377132188
cancer1927471001214593148192241273
has22274710012155103141
remained2395471001213282165212235290340396
one28184710012155110160
of3004471001215584
the3114471001213388138
few3278471001212979152
in3456471001212478
which35614710012173129151195250
novel3404850012155110157205229
types589485001213382139190229
of838485001215483
anticancer9414850012148103134157201249304349397429
therapy1390485001213388138170218274320
(immunotherapy1730485001212850133216270325379412466516548597653699
or2448485001215588
targeted2555485001213382114169219252300357
therapy2932485001213388137170218274320
with3272485001217396129184
tyrosine3475485001213383116170209231286336
kinase340499001214771126173212262
inhibitors)619499001212378132155211234266320352392416
had10524990012156103159
not12284990012156110143
been13884990012156107157212
implemented16174990012124106162186236319369424456504561
into2195499001212378110163
the2375499001213388138
therapeutic2530499001213387137169217274324379411434478
algorithm.3025499001214871126181213236269324406427
This34694990012149105128166
was36524990012173121160
logically340513001212478134156200248271294340
associated697513001214886125179224246293325374430
with1144513001217396129183
a13445130012148
limited1409513001212346128151183232288
progress1714513001215789143199230279318357
in2087513001212478
the2182513001213387137
parameters23365130012157105136184267316349398430469
of2822513001215583
overall29225130012155101150182230252275
survival,3214513001213993125175198246294316336
specifically356751300121399514619121334052700121295497144167189235
the591527001213286135
5-year742527001215081127175222253
survival1011527001213992123173196243290312
rates1339527001213279111158196
of1551527001215583
patients.16505270012156103134156205259290329350
Currently,20165270012157108140172220274305327373388
we24205270012173121
are2557527001214779127
witnessing2700527001217395127181230268306327381436
the3152527001213286135
introduction3303527001212377108139192248301345379400454508
of340541001215584
adjuvant4515410012148104128182230278333365
immunotherapy8435410012123106189243298353385440490522570627673
after1543541001214877112161194
chemoradiotherapy1764541001214599149233287320368424447501534589639671719775821
in2613541001212378
real-world2718541001213382130153184258312344368424
clinical316954100121456790145167212260283
practice3479541001215789138182217239284332
for340555001212984116
limited-stage474555001212446129151184233290321360394442497547
small10395550012140122170193215
cell1272555001214594117140
lung1430555001212378132188
cancer.1636555001214593148192241273289
This19435550012149105128166
option21275550012155111144167221276
was24215550012174122160
achieved2599555001214893147170219266315372
based29895550012157105144193250
on32575550012155110
the3385555001213388138
results3541555001213282121175198230270
of340569001215583
the446569001213387137
ADRIATIC6065690012161127180204264307331389
clinical101756900121456890145168212260283
trial132256900121336588136159
in1503569001212378
which16035690012174129152196250
durvalumab18765690012156110142193241264318401448505
(a2403569001212873
PD-L124985690012153118152200243
inhibitor)2763569001212478133156212235268321354379
administered31655690012148104187209264287325358407439489545
in3733569001212378
patients3405830012157105137160209265296336
after701583001214977113162194
concomitant920583001214598153198251334357389438492524
platinum-based1469583001215781128160183238292374406464512551601657
chemoradiotherapy,21515830012145100150233287320368424447501533588638670719775821836
in3012583001212378
whom31155830012174129184267
there3407583001213388137170219
was36515830012174122160
no3405970012155110
progression469597001215789143200232281320359381435491
after979597001214876112161193
the1191597001213388138
initial1348597001212378100133155203226
treatment,1593597001213365114162194276326381413434
was20465970012173121160
shown2225597001213994149221276
to2520597001213387
have26265970012155103149197
a28425970012149
statistically2909597001214073122154176214248270315363386408455
significant3383597001214062118172195224249294342396428
improvement3406110012123106162195249295344427477532564
in931611001212478
the1037611001213387137
primary1201611001215790113195243275325
endpoints15536110012150105161218273296351382422
–20036110012150
time2080611001213355138188
to2295611001213387
progression2409611001215789143199232281320358381435491
and29276110012148103159
overall31136110012155101150182230253276
survival3416611001214093126176200247295318
–37616110012150
compared340625001214598180236285316365422
with779625001217396129183
the979625001213387137
control1133625001214497152184216270293
arm1443625001214880163
with1622625001217497129184
placebo.1822625001215781128172220277332351
This21896250012150106128166
fact2372625001212977121156
was25456250012173121159
reflected2721625001213382111136186231266314371
by31096250012156102
the3228625001213387137
regulatory3382625001213281137192214262293347379429
authorities3406390012148102135190244277300332355404443
of803639001215584
the907639001213388138
European10656390012149102134188245295343397
Union14826390012165120142197252
in1754639001212378
February/March1852639001214997154186241289321370401480528560604659
2025,25316390012151101149199218
which27696390012174129151196250
recommended3039639001213382127181264346396452508558614
the3673639001213388138
use340653001215594144
of504653001215583
durvalumab6076530012157111143194242265319402449505
in1133653001212378
this1231653001213388110148
setting.1400653001213989122157180234290310
Key3406690012461112163
words:5196690012476132170230273298
small8346700012139121169192215
cell1066670001214593117140
lung1223670001212378132188
cancer1428670001214593147192240273
(SCLC),1718670001212874132177232261279
limited2015670001212346128151184232289
stage,2321670001214073121177227246
immunotherapy,25856700012123105188242296351383438488520568624670686
durvalumab.32886700012156110142193241264318400448504523
Úvod3407030014780142208279
Malobuněčný4807200010972116136185236286335380420469509
karcinom1009720001094286114154174223272347
plic137572000109517292132
(SCLC1526720001092668119160210
–17557200010945
small18197200010936110153173193
cell340734001094084105126
lung489734001092170120170
cancer)682734001094184133173217246269
je975734001092267
histologickým1065734001095071105135183204254304325364406450526
podtypem16147340010952102153182226278323398
karcinomu340748001094286115154174223272347396
plic,75274800109517292132150
jehož918748001092267117166203
vznik1137748001094383132153194
je1347748001092266
těsně1429748001093074109158203
spjat1647748001093686107150179
s18417480010936
kuřáckým1893748001094291340762001092973112154199274
návykem.637762001095093135180222266340359
Na10207620010959102
buněčné11467620010951100150194235284329
úrovni1499762001094978127169219239
je1762762001092166
charakterizován1852762001094089132340776001092971112143185214234271318359401449
velmi803776001094385106178198
rychlou1015776001092972110158178226274
proliferací,1303776001095079126147166191235263305344363381
což1697776001094087123
vede1833776001094386136180
k21407060010942
agresivnímu2195706001094392120163197217259308327400448
biologickému2656706001095171119139187237257295336378452499
chování.3169706001093987135176219267286304
U34867060010958
cca3557706001094078120
2/33690706001094677121
pacientů2140720001095195134155199249277326
jsou2485720001092257106155
v26597200010944
době27227200010951100151196
stanovení2938720001093565109158207249292342362
diagnózy3320720001095071113163212261298343
přítomné36827200010951801012140734001093079155205251
radiologicky2415734001093073125145195217267318339379421467
detekovatelné2906734001095197127171214263305349378423444494540
vzdálené3470734001094484135179200245296341
metastázy,21407480010976122152196232262306346391405
časnější2570748001094184120170215237272293
stadia,2887748001093667111162183226245
s31567480010937
potenciálně32177480010952102132177227268288332353403448
kurabilním,36907480010942932140762001092973123144164213234308326
multimodálním24857620010975124145174194268317368411432481501575
léčebním3079762001092166107150201251271345
záměrem,3443762001093983157202231275350368
jsou2140776001092256105155
zachycena2312776001093983123172212251295344387
jen2716776001092267116
v28507760010943
cca2910776001094079122
1/33050776001094671117
případů3184776001095181101152195245294
(1,349577600109266781
2).359377600109466985
DECLARATIONS:4068201008648871301662142563043393604124625014570202008514
Declaration406821500874987120141179206244271291333375
of445721500874066
originality:45372150087406888130150192230251271298337356
The406822600853473109
manuscript418822600855891130168195227249266306329
is452822600851744
original45832260085386178117133172205222
and481622600853472112
has49392260085387299
not50502260085387699
been516122600853975110149
published532222600853977117134150177216251291
or406823700853862
submitted414523700852867108167184208234269310
elsewhere.44702370085355381117169209245269305320
Ethical406825100873764107127160198218
principles43002510087427090132165185228249287319
compliance:463325100873173134177197218256298330368387
The406826200853678116
authors420526200853475100142183208238
attest44642620085356087124153179
that466426200852465101126
their481126200852465103121146
study49782620085295595138173
was517326200855389118
approved531226200853577120145186221258301
by406827300854073
the41582730085236399
local42742730085175689124141
Ethical44322730085345898115147182199
Committee464827300854179139198215239265300337
and500227300853373113
is513227300851745
in519427300851656
compliance526727300853169129169187204239278311346
with40682840085537298140
human423628400854081143180221
studies44862840085285596139157195226
and474028400853577119
animal48882840085347695156193212
welfare512828400855391110133170196234
regulations53902840085236110414516420140682950085234080120148
of423529500853960
the43152950085236399
authors’44342950085347397136176200229244
institutions46982950085165684109126150189213231270310338
as505629500853462
well513829500855187104122
as527929500853462
with53612950085526993133
the55142950085236299
World406830600856099124142184
Medical427330600855795137155188224242
Association453530600854474104144178196231256273314355
Declaration491130600854785119136172196232257274315356
of528830600853961
Helsinki537030600854684102131149189224243
on406831700853878
Ethical41653170085355898115147182199
Principles43833170085376178117150167207225261290
for46923170085205983
Medical479431700855693134151183218235
Research504831700853874102139173197229268
Involving53353170085175690128146181198238278
Human406832800854685145179219
Subjects430732800853474114132168201227256
adopted458332800853474114155179215256
by485832800854074
the49523280085236399
18th507132800853669514132900501437
WMA5198328008559116160
General537832800854582122158182217235
Assembly406833900854475105143204247266302
in439333900851758
Helsinki,447433900854785104134152193228248264
Finland,47613390085355394113149190232249
in503333900851758
June511533900852667109147
1964,528533900853771110150166
with54743390085537297139
subsequent406835000852867107136172213252288328352
amendments,443735000853493130169210269305345369398414
as486835000853462
well494835000855287105122
as508835000853362
with51673500085526993133
the53183500085236298
ICMJE543435000851759116143179
Recommendations406836100853977112153216278317359402439465483525568598
for46973610085226389
the481836100852466104
Conduct,495436100854283125168210245272290
Reporting,527536100853978121163189217236278321338
Editing,40683720085347491115132172212227
and430837200853373113
Publication443437200853776117134151183218242259298338
of478537200853859
Scholarly485737200853467106146163198221239273
Work514237200856097121155
in531037200851656
Medical537837200855693134151183218235
Journals,406838300852666105129169204221249265
updated435338300853980121155179215256
in462938300851656
December470538300854683116151211252289313
2018,503738300853673107140156
including52133830085165689106145186203243283
patient55163830085407540683940085234076116140
consent422239400853270110138174214238
where447539400855191127151187
appropriate.467739400853474115139178219243260295318354369
Conflict406840800874282124149171191223251
of433440800874065
interest44134080087196288126154192224251
and467840800873779122
financial48144080087244587125167200220258279
disclosures:51074080087416293126147188220261289327359378
None.406841900854686126162177
Funding/Support:406843300873777119162183225267291329371414457499526554574
None.406844400854686126162177
Cit.4068714008541588297
zkr:41807140085306489105
Onkologie.429971400864991127167186227268287324342
2025;19(4):214-218465571400863876113151167203238260296317334372408442467503538574
https://doi.org/10.36290/xon.2025.040406872500853962881291571721982194284725008641811004385725008514547811714345287250086387390130169206244283307342382423441481519556594611650689728
Článek40687360085415892132168202
přijat4285736008539638198132156
redakcí:445673600852359100134168199216231
19.47017360085366982
8.479873600853652
2025486573600853672107144
Článek40687470085415892132168202
přijat4285747008539638198132156
k4456747008533
tisku:45047470085234068101141156
29.46757470085367285
8.477574700853652
2025484274700853672107143
MUDr.4068766008759108158186202
Juraj42847660087297199137157
Kultan445576600874384104132170212
Juraj.Kultan@fnol.cz40687780085266589124141157197235253277312351404426466506523539571603